home / stock / ikna / ikna news


IKNA News and Press, Ikena Oncology Inc. From 03/12/24

Stock Information

Company Name: Ikena Oncology Inc.
Stock Symbol: IKNA
Market: NASDAQ

Menu

IKNA IKNA Quote IKNA Short IKNA News IKNA Articles IKNA Message Board
Get IKNA Alerts

News, Short Squeeze, Breakout and More Instantly...

IKNA - Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for 2H 2024 including additional data from EHE patients in dose escalation and initial mesothelioma patient data IK-595 Phase I dose escalati...

IKNA - Expected US Company Earnings on Tuesday, March 12th, 2024

Koninklijke KPN NV (KKPNF) is expected to report for Q4 2023 ECA Marcellus Trust I Unit (ECTM) is expected to report for Q4 2023 San Juan Basin Royalty Trust (SJT) is expected to report for Q4 2023 Avenir Wellness Solutions Inc (AVRW) is expected to report for Q4 2023 Carmell Corp...

IKNA - Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference

BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in a targeted oncology panel at t...

IKNA - Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer

Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertise Dr. Germa will drive clinical development strategy and oversee the execution of targeted oncology programs, IK-930 and IK-595 Serg...

IKNA - Ikena to cut 35% of workforce, extend cash runway into 2H 2026

2024-01-18 17:18:25 ET More on Ikena Oncology Ikena tumbles after early data for lead asset, Q3 financials Seeking Alpha’s Quant Rating on Ikena Oncology Historical earnings data for Ikena Oncology Financial information for Ikena Oncology For f...

IKNA - Ikena Oncology Outlines Key Priorities and Provides Corporate Updates

IK-930 optimized formulation now in the clinic; on track to deliver additional monotherapy data in 2H 2024 IK-595 first cohort treated and cleared safety evaluation window Focused execution on core targeted oncology clinical programs; organizational reallocation of resources fro...

IKNA - GOTU, SMR and LDI are among pre market gainers

2023-12-15 08:46:33 ET Aurora Technology Acquisition  ( ATAK ) +50% . Brilliant Acquisition  ( BRLI ) +27% . Ikena Oncology ( IKNA ) +24% . SportsMap Tech Acquisition  ( SMAP ) +14% . Pineapple Financial  ( PAPL ) +1%...

IKNA - DTCK, CDIO and MOBV among mid-day movers

2023-11-09 12:48:14 ET Gainers: Intelligent Bio Solutions ( INBS ) +149% . Pineapple Financial ( PAPL ) +87% . Ramaco Resources ( METC ) +34% . Tempest Therapeutics ( TPST ) +30% . Fitell Corp ( FTEL ) +32% . Honest Company (...

IKNA - Ikena tumbles after early data for lead asset, Q3 financials

2023-11-09 12:18:43 ET More on Ikena Oncology Ikena Oncology a new buy at Wedbush on cancer asset with new target Seeking Alpha’s Quant Rating on Ikena Oncology Historical earnings data for Ikena Oncology Financial information for Ikena Oncology ...

IKNA - Atara Biotherapeutics, Ikena Oncology among healthcare movers

2023-11-09 10:00:37 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector a...

Previous 10 Next 10